A detailed history of Arkadios Wealth Advisors transactions in Crispr Therapeutics Ag stock. As of the latest transaction made, Arkadios Wealth Advisors holds 11,295 shares of CRSP stock, worth $459,932. This represents 0.03% of its overall portfolio holdings.

Number of Shares
11,295
Previous 10,771 4.86%
Holding current value
$459,932
Previous $581,000 8.78%
% of portfolio
0.03%
Previous 0.04%

Shares

16 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Oct 24, 2024

BUY
$44.62 - $62.75 $23,380 - $32,881
524 Added 4.86%
11,295 $530,000
Q2 2024

Jul 29, 2024

SELL
$51.17 - $68.18 $4,912 - $6,545
-96 Reduced 0.88%
10,771 $581,000
Q1 2024

Apr 30, 2024

SELL
$60.67 - $89.12 $9,585 - $14,080
-158 Reduced 1.43%
10,867 $740,000
Q4 2023

Jan 24, 2024

SELL
$38.62 - $72.18 $9,075 - $16,962
-235 Reduced 2.09%
11,025 $690,000
Q3 2023

Oct 13, 2023

BUY
$45.39 - $59.0 $5,900 - $7,670
130 Added 1.17%
11,260 $511,000
Q2 2023

Jul 26, 2023

SELL
$43.47 - $67.77 $24,256 - $37,815
-558 Reduced 4.77%
11,130 $624,000
Q1 2023

May 02, 2023

SELL
$41.0 - $56.12 $1,804 - $2,469
-44 Reduced 0.38%
11,688 $528,000
Q4 2022

Jan 11, 2023

SELL
$39.19 - $65.67 $51,025 - $85,502
-1,302 Reduced 9.99%
11,732 $0
Q3 2022

Oct 21, 2022

SELL
$61.1 - $83.78 $13,197 - $18,096
-216 Reduced 1.63%
13,034 $852,000
Q2 2022

Jul 14, 2022

BUY
$43.23 - $73.83 $1,123 - $1,919
26 Added 0.2%
13,250 $805,000
Q1 2022

May 02, 2022

BUY
$53.19 - $79.24 $21,488 - $32,012
404 Added 3.15%
13,224 $830,000
Q4 2021

Feb 03, 2022

BUY
$70.09 - $111.29 $886,638 - $1.41 Million
12,650 Added 7441.18%
12,820 $971,000
Q2 2021

Jul 28, 2021

BUY
$100.84 - $161.89 $17,142 - $27,521
170 New
170 $27,000
Q1 2021

Apr 26, 2021

SELL
$110.72 - $210.04 $3,764 - $7,141
-34 Closed
0 $0
Q4 2020

Feb 09, 2021

BUY
$79.67 - $173.23 $1,115 - $2,425
14 Added 70.0%
34 $5,000
Q1 2020

May 14, 2020

BUY
$33.68 - $62.53 $673 - $1,250
20 New
20 $848,000

Others Institutions Holding CRSP

About CRISPR Therapeutics AG


  • Ticker CRSP
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 78,009,296
  • Market Cap $3.18B
  • Description
  • CRISPR Therapeutics AG, a gene editing company, focuses on developing gene-based medicines for serious diseases using its proprietary Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) platform. Its CRISPR/Cas9 is a gene editing technology that allows for precise directed changes to genomic DNA....
More about CRSP
Track This Portfolio

Track Arkadios Wealth Advisors Portfolio

Follow Arkadios Wealth Advisors and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Arkadios Wealth Advisors, based on Form 13F filings with the SEC.

News

Stay updated on Arkadios Wealth Advisors with notifications on news.